About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Corneal Nerves After Treatment With Cenegermin | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04627571

Corneal Nerves After Treatment With Cenegermin

Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in t...

Lead sponsor: University of California, Los Angeles•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

University of California, Los Angeles

Collaborators

Dompé Farmaceutici S.p.A

Cenegermin (OxervateTM) is a recombinant human form of nerve growth factor developed by Dompé Farmaceutici S.p.A. for patients who are diagnosed with corneal epithelial defects due to moderate to severe stages of NK.

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients ≥18 years of age; AND
•2. Persistent corneal epitheliopathy that is refractory to treatments for ≥2 weeks; AND
•3. Evidence of decreased corneal sensitivity, defined as ≤45mm on Cochet-Bonnet esthesiometer, within the area of the persistent corneal epitheliopathy; AND
•4. Evidence of decreased corneal sensitivity, defined as above, in ≥1 corneal quadrant outside the persistent corneal epithelial defect.

Exclusion Criteria

•1. Patients with severe neurotrophic keratopathy characterized by corneal stromal ulceration involving over 75% of the total central corneal thickness and impending perforation.
•2. Patients who have used cenegermin eyedrops, autologous serum eyedrops, plasma-rich plasma eyedrops, or umbilical cord eyedrops for the treatment of neurotrophic keratopathy 8 weeks prior to study recruitment.
•3. Corneal surgery (including keratoplasty or refractive surgical procedures) within three months before study enrollment.
•4. Presence of concurrent bacterial or fungal infection.

Related studies

RECRUITINGPhase 1/2

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

NCT06999733 · Neurotrophic Keratitis

OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

NCT04573647 · Neurotrophic Ulcer, Neurotrophic Keratitis, and more

COMPLETEDPhase 2

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558 · Neurotrophic Keratitis

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

NCT06364657 · Sjogren's Syndrome, Dry Eye, and more

WITHDRAWNPhase 4

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

NCT06411145 · Neurotrophic Keratitis, Neurotrophic Keratopathy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 1, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment8

Start dateMay 2022

Last updatedApr 1, 2025

Condition

Neurotrophic Keratitis

Locations shown

University of California, Los Angeles

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 1, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions